JW Holdings Corporation

A096760

KR7096760004

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2,980 ^KRW	-1.00%		+0.68%	-14.61%

Mar. 20	JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023	MT
Mar. 18	JW Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI

JW Holdings Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 13, 2023 at 11:52 pm EST

JW Holdings Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 2,649.54 million compared to KRW 4,005.81 million a year ago. Net income was KRW 2,424.14 million compared to KRW 8,691.78 million a year ago. Basic earnings per share from continuing operations was KRW 34.3137 compared to KRW 123.5294 a year ago. Basic earnings per share was KRW 34.3137 compared to KRW 123.5294 a year ago.
For the nine months, sales was KRW 12,099.92 million compared to KRW 14,788.07 million a year ago. Net income was KRW 5,987.91 million compared to KRW 14,757.96 million a year ago. Basic earnings per share from continuing operations was KRW 83.3333 compared to KRW 210.7843 a year ago. Basic earnings per share was KRW 83.3333 compared to KRW 210.7843 a year ago.

Latest news about JW Holdings Corporation

JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023	Mar. 20	MT
JW Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Oberoi Realty Ties Up with Marriott International for Two Developments in India's Mumbai Metropolitan Area	Feb. 16	MT
Fresh Vine Wine to Acquire Notes Live in All-Stock Deal	Jan. 29	MT
CJ Logistics Secures Distribution Deal for JW Pharm's Intravenous Solutions	Jan. 22	MT
JW (Cayman) Therapeutics Signs Collaboration Deal for Development of Autoimmune Disease Treatment	Jan. 03	MT
JW Therapeutics CFO Resigns	Dec. 18	MT
JW Holdings Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Host Hotels & Resorts raises full-year adjusted FFO outlook on higher hotel occupancy	Nov. 01	RE
Safety Shot Gets US Patent for Hair Loss Treatment JW-700	23-10-25	MT
South Korean Shares Touch Seven-Month Low on Concerns over US Fed Rate Hikes	23-10-20	MT
JW Pharmaceutical Faces Potential Fine of Nearly 30 Billion Won for Alleged Illegal Rebates	23-10-20	MT
Kering: new creative director at Alexander McQueen	23-10-03	CF
JW (Cayman) Therapeutics to Expand Strategic Alliance with Cell and Gene Therapy Firm	23-09-13	MT
JW Therapeutics' H1 Attributable Loss Narrows on Higher Revenue	23-08-29	MT
JW Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Los Angeles-area hotel workers go on strike	23-07-04	RE
Ryman Hospitality Properties Units Complete $400 Million of 7.25% Senior Notes Offering	23-06-22	MT
Ryman Hospitality Properties Completes Upsized Public Offering for $396 Million in Proceeds	23-06-09	MT
Ryman Hospitality Properties Units Price Upsized $400 Million Senior Notes Offering	23-06-07	MT
Ryman Hospitality Properties Units to Offer $300 Million in Senior Unsecured Notes	23-06-07	MT
Ryman Hospitality Properties Prices Upsized Common Stock Offering	23-06-07	MT
Ryman Hospitality Properties Launches Common Stock Offering to Fund JW Marriott San Antonio Acquisition	23-06-06	MT
Ryman Hospitality to buy Texas-based resort from Blackstone for $800 million	23-06-05	RE
Financials Down as Relief Rally in Regional Banks Fades -- Financials Roundup	23-06-05	DJ

Chart JW Holdings Corporation

Duration

Period

More charts

Company Profile

JW Holdings Corp is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company operates its business through four segments. The Pharmaceutical segment is involved in the manufacturing and sale of pharmaceuticals. Its major products include antibiotics, antifungal agents, blood and body fluids substitutes, hyperlipidemia drugs, electrolyte additives, angina pills, and digestive medicines. The Medical Equipment segment manufactures and sells medical equipment such as diagnostic equipment, diagnostic reagents, surgical operating tables, and surgical mooyoung lamp. The Holding Business segment manages affiliated companies within the group. The Other segment is involved in the manufacturing and sale of automotive supplies, as well as the real estate investment.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
JW HOLDINGS CORPORATION	-14.61%	156M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B